Good earnings report, not spectacular but still growing despite the exchange impact. I will keep my shares and look forward to steady earnings and dividend growth.
Galectine 3 test for HF to be supplied through with ABT Architect platform. The automated test will become standard test for Heart failure patients globally (ca 30M people, to test twice a year, at $30 per test = $1.8B revenue potential), as highly predicitive of HF and recenlty cleared by the FDA (on Dec 30th 2014). BGMD owning the IP rights of the automated Galectine 3 test has $21M market cap..., I leave it to you to guess where BGMD PPS is heading (+ 60% only last week)
Sentiment: Strong Buy
EPS all four quarters 2014 beat estimates and 2015 guidance was solid and in line with estimates. Abbott looks to be pretty solid going forward. Good growth, continues good margin improvements and solid EPS growth. Did not decrease guidance like some many international companies are doing this quarter.
Call Abbott Investor Relations up and see if this direction is really coming from Abbott Laboratories. Sounds to me that it could very well be your brokerage company not wanting to deal in lots smaller than 100 shares. I ran into this situation several years ago with a broker (Not with Abbott shares but with some other stocks) giving me the same pitch and I immediately transferred everything in the account to my other broker.
Good, I'm happy. Strange how when you speculate on currency risk, the rah-rahs come out and "thumbs down" your post. Been long for many years, but sold ABBV before Hep C approval.
No divvy increase this time around, I noticed.
If you are referring to the Abbott Dividend, it was increased 2 cents per share per quarter (9%) starting with the February dividend payment.
Excellent comment and I thank you.
I called my broker and he re-assured me that it wasn't them that initiated that e-mail.
He also stated and it made sense to me that ABT was the originator because of two facts.
One they do not care to have the administraive responsibility for small accounts and two this action provides them to have more shares available to sell.
It costs me $7.00 to buy shares and $7.00 to sell. Through the years I have come to know the manager and assistant manager and I trust them both.
When this security tops out I may make a decision.
Trade wisely and I suggest to anybody to first call ABT and ask them what is their policy regarding limiitation on the amount of shares they require investors to hold.
In closing I say this is a very sad experience for a senior citizen.
There is positive news with BGMD. You want to do a little DD on it. The way
Kingkongdingdong is putting the news out there makes it look like
he has Downs Syndrome. He makes BGMD look bad...
Mylan to buy Abbott business line in $5.3B deal - Abbott will own about 21% of the combined Mylan company which will be called Mylan NV but does not intend to remain a long-term shareholder. Shares of Mylan NV will trade on the Nasdaq under Mylan's existing ticker symbol, "MYL."